Oncopeptides – Journal of Cancer Research and Clinical Oncology: Exceptional long-term responses to Pepaxti
Stockholm – October 16, 2025 – Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces the publication of three case reports in the Journal of Cancer Research and Clinical Oncology, demonstrating long-lasting clinical responses to melflufen (branded in Europe as Pepaxti) in patients with relapsed or refractory multiple myeloma (RRMM).
The peer-reviewed article, authored by European investigators involved in the pivotal OCEAN and HORIZON studies, describes three heavily pretreated patients who achieved unusually durable responses – including complete and stringent complete responses lasting more than four years – while receiving melflufen plus dexamethasone.
“These exceptional cases illustrate that melflufen can induce deep and durable remissions in selected patients, even in the context of advanced disease,” says Dr. Elena Zamagni, first author of the publication and Associate Professor at the University of Bologna, Italy. “Although such long-term outcomes are rare, they highlight the drug’s potential role as a meaningful option in the modern myeloma treatment landscape.”
“These data complement the clinical evidence base from the OCEAN and HORIZON studies and underscore Pepaxti’s relevance for patients who may not be eligible for, or have access to, novel immunotherapies,” says Stefan Norin, Chief Medical Officer at Oncopeptides. “While these are individual observations, they demonstrate that Pepaxti can deliver sustained benefit and durable remission in real-world settings for certain patients.”
The article, “Exceptional long-term responses from OCEAN and HORIZON trials: melflufen-dexamethasone as an expansion of treatment options for relapsed/refractory multiple myeloma in the era of new immunotherapies”, is available online.
For more information, please visit oncopeptides.com, where you will also find a Q&A for investors.
For more information, please contact:
David Augustsson, Director of IR and Communications, Oncopeptides AB (publ)
E-mail: ir@oncopeptides.com
Cell phone: +46 76 229 38 68
About Oncopeptides
Oncopeptides is a Swedish biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers.
The company uses its proprietary Peptide Drug Conjugate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East and Africa and elsewhere.
Oncopeptides is also developing several new compounds based on its two proprietary technology platforms PDC and SPiKE.
The company was founded in 2000, has about 80 employees with operations in Sweden, Germany, Austria, Spain and Italy. Oncopeptides is listed on Nasdaq Stockholm with the ticker ONCO.
For more information see: www.oncopeptides.com
About Pepaxti
Pepaxti® (melphalan flufenamide, also called melflufen) has been granted Marketing Authorization, in the European Union, the EEA-countries Iceland, Lichtenstein and Norway, as well as in the UK. Pepaxti is indicated in combination with dexamethasone for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38 monoclonal antibody, and who have demonstrated disease progression on or after the last therapy. For patients with a prior autologous stem cell transplantation, the time to progression should be at least 3 years from transplantation.
